A
Anthony Accurso
Researcher at Johns Hopkins Bayview Medical Center
Publications - 6
Citations - 975
Anthony Accurso is an academic researcher from Johns Hopkins Bayview Medical Center. The author has contributed to research in topics: Type 2 diabetes & Buprenorphine. The author has an hindex of 4, co-authored 6 publications receiving 790 citations. Previous affiliations of Anthony Accurso include SUNY Downstate Medical Center.
Papers
More filters
Journal ArticleDOI
Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base
Richard D. Feinman,Wendy Pogozelski,Arne Astrup,Richard K. Bernstein,Eugene J. Fine,Eric C. Westman,Anthony Accurso,Lynda A. Frassetto,Barbara A. Gower,Samy I. McFarlane,Jørgen Vesti Nielsen,Thure Krarup,Laura R. Saslow,Karl S. Roth,Mary C Vernon,Jeff S. Volek,Gilbert B. Wilshire,Annika Dahlqvist,Ralf Sundberg,Ann Childers,Katharine Morrison,Anssi H Manninen,Hussain Dashti,Richard J. Wood,Jay Wortman,Nicolai Worm +25 more
TL;DR: 12 points of evidence supporting the use of low-carbohydrate diets as the first approach to treating type 2 diabetes and as the most effective adjunct to pharmacology in type 1 are presented and represent the best-documented, least controversial results.
Journal ArticleDOI
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal
Anthony Accurso,Richard K. Bernstein,Annika Dahlqvist,Boris Draznin,Richard D. Feinman,Eugene J. Fine,Amy Gleed,David B Jacobs,Gabriel Larson,Robert H. Lustig,Anssi H Manninen,Samy I. McFarlane,Katharine Morrison,Jørgen Vesti Nielsen,Uffe Ravnskov,Karl S. Roth,Ricardo Silvestre,James R. Sowers,Ralf Sundberg,Jeff S. Volek,Eric C. Westman,Richard J. Wood,Jay Wortman,Mary C Vernon +23 more
TL;DR: The argument is made that a re-evaluation of the role of carbohydrate restriction, the historical and intuitive approach to the problem, may provide an alternative and possibly superior dietary strategy that improves glycemic control and reduces insulin fluctuations which are primary targets.
Journal ArticleDOI
The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
TL;DR: It is suggested that buprenorphine doses greater than 16 mg/day are more effective for some patients and that dose limits at this level or lower are harmful.
The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with
TL;DR: In this paper, the effect of a change in payer policy, in which the insurer of a subset of patients in an office-based practice imposed a maximum sublingual buprenorphinedose of 16mg/day, thereby forcing thosepatients on higher daily dosesto decrease their dose.
Journal ArticleDOI
Corrigendum to "Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base" [Nutrition 31 (2015) 1-13].
Richard D. Feinman,Wendy Pogozelski,Arne Astrup,Richard K. Bernstein,Eugene J. Fine,Eric C. Westman,Anthony Accurso,Lynda A. Frassetto,Barbara A. Gower,Samy I. McFarlane,Jørgen Vesti Nielsen,Thure Krarup,Laura R. Saslow,Karl S. Roth,Mary C Vernon,Jeff S. Volek,Gilbert B. Wilshire,Annika Dahlqvist,Ralf Sundberg,Ann Childers,Katharine Morrison,Anssi H Manninen,Hussain Dashti,Richard J. Wood,Jay Wortman,Nicolai Worm +25 more